Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the industry’s growth of 2.9%. While shares hit a 52-week high of $49.62 on June 23, 2025, it dipped after the company reported second-quarter results on July 28.Nonetheless, despite the slide, the stock...